India's blood safety architecture under the Drugs and Cosmetics Act is ill-equipped to protect vulnerable populations such as thalassemia patients. Discuss the administrative and technological reforms needed.

Q. India's blood safety architecture under the Drugs and Cosmetics Act is ill-equipped to protect vulnerable populations such as thalassemia patients. Discuss the administrative and technological reforms needed. (15 marks, 250-350 words)

Human blood is regulated as a "drug" under the Drugs and Cosmetics Act, 1940, with blood centres licensed by State Drug Controllers under Schedule F, Part XII-B [1]. Yet mandatory screening rests on serological (ELISA) tests alone, leaving a window period during which infected blood tests negative — a gap that repeatedly harms thalassemia patients, who need transfusions every 2–4 weeks for life [2].

Why the present architecture falls short - Technological lag: ELISA detects antibodies, not virus. A Madhya Pradesh centralized NAT model found 1 in 168 seronegative units to be NAT-reactive, i.e. infectious blood cleared by existing tests [3]. - Fragmented regulation: licensing sits with CDSCO/State Drug Controllers, standards with the NBTC and NACO, and delivery with States (Health, Entry 6, List II) — diffusing accountability [4]. - Uneven capacity: NAT facilities cluster in urban tertiary centres; district and rural blood centres lack infrastructure and trained manpower. - Judicial limits: in March 2026 the Supreme Court declined to mandate NAT, citing lack of expertise in medical science and costs, and directed the petitioner to State Health Secretaries [5] — confirming that reform must come through the executive route.

Reforms needed - Technological: phase in Nucleic Acid Testing through a hub-and-spoke model — regional NAT hubs serving clustered blood centres, which cuts per-unit cost without equipping every bank [3]; add leucodepletion for repeat-transfusion patients. - Administrative: prioritise thalassemia-serving centres first; strengthen NBTC standards and external quality assessment, which WHO treats as the core of quality-assured screening [6]; build a national donor and haemovigilance registry for notification and traceability; expand voluntary, repeat, non-remunerated donation to lower baseline infection prevalence [6].

Safe blood is an integral part of the right to life under Article 21, but it is realised through calibrated executive action, not judicial fiat. A phased, cost-graded NAT rollout anchored in a strengthened NBTC framework can extend protection to the most transfusion-dependent first — advancing SDG-3's promise of health security for the vulnerable.

(~330 words)

Sources: 1. CDSCO, "Regulatory Requirements of Blood and/or Its Components Including Blood Products in India" — blood as a "drug"; licensing under Schedule F, Part XII-B by State Drug Controllers 2. WHO EMRO, "Blood transfusion and hepatitis: what does it take to prevent new infections?" — window-period risk in serological screening; transfusion-dependent patients 3. "Blood Safety: The Madhya Pradesh Centralized Nucleic Acid Testing (NAT) Model for Blood Donor Screening" — 1 in 168 seronegative samples NAT-reactive; hub-and-spoke feasibility 4. National Blood Transfusion Council (NBTC), NACO, MoHFW — NBTC/NACO as standard-setting bodies for blood safety 5. "Supreme Court declines plea to make nucleic acid tests compulsory at blood banks" — March 2026 order; institutional-competence and cost reasoning; liberty to approach State Health Secretaries 6. WHO Fact Sheet, "Blood safety and availability" — quality-assured screening, external quality assessment, voluntary unpaid donation